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P AT E N T S

Law, history and lessons in the CRISPR patent conflict
Jacob S Sherkow
Predicting the outcome of the ongoing patent disputes surrounding genome-editing technology is equal parts
patent analysis and history.
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enome-editing technology based on
clustered, regularly interspaced, short
palindromic repeats (CRISPR) and CRISPRassociated protein 9 (Cas9) has generated great
excitement in both academia and industry. But
a potential patent dispute between two sets of
inventors has left the biotech community pondering its fate. Understanding several facets of
patent law and history may provide some lessons about the probable—and best—outcome
for the dispute.
CRISPR and the patent landscape
The CRISPR-Cas9 genome-editing system is
based on an endogenous, prokaryotic immune
response to foreign nucleic acids, such as viral
genomes or plasmids. When presented with
viruses or plasmids, some prokaryotes integrate short fragments of the foreign sequence
into one or more CRISPR loci, and then transcribe the loci and process the output to form
short CRISPR RNAs (crRNAs). The newly created crRNAs then direct Cas9, a DNA nuclease, to cleave future foreign nucleic acids on the
basis of sequence complementarity. The system’s ability to precisely introduce foreign DNA
sequences makes CRISPR-Cas9 an incredibly
versatile, effective system for genomic editing.
That versatility, and the potential to use
CRISPR-Cas9 for practical (and profitable)
in vivo applications, has led to two competing
patent claims on the CRISPR-Cas9 system. The
first stems from work led by Jennifer Doudna,
at the University of California, Berkeley (UC
Berkeley), and Emmanuelle Charpentier, at
the Helmholtz Centre for Infection Research
in Germany, for a method of exploiting the
system for genome editing in vitro1. Their
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patent application, which claims a priority date
of May 25, 2012, includes 155 claims, encompassing numerous applications of the system
for a variety of cell types2. The second comes
from Feng Zhang of MIT on a method for using
CRISPR-Cas9 for genome editing in eukaryotic
cells3. Zhang’s patent, which claims a priority
date of December 12, 2012, has already been
issued4.
Since these filings, there has been a flurry
of patent applications related to CRISPR-Cas9.
More than a dozen new patents and 100 patent
applications have claimed or described applications for the CRISPR-Cas9 system. Zhang
alone has received eight CRISPR-Cas9 patents,
all from ‘fast-tracked’ applications and drafted
to very broad applications of the technology.
Some of these patents are directed to more specific applications, such as the patent claiming
the use of the technology to treat Huntington’s
disease5.
Challenges to the patents
The breadth and competing claims of these
patents and patent applications pose several
challenges to their inventors—and to the
biotech community at large. The first concerns the priority of the fomenting patent
dispute between Doudna and Charpentier, on
one side, and Zhang on the other. Currently,
the patent application from Doudna and
Charpentier appears to have priority over
Zhang’s earliest issued patent—theirs claims a
priority date of May 25, 2012, whereas Zhang’s
claims a priority date of December 12, 2012.
Assuming Zhang’s claims overlap with those
of Doudna and Charpentier, this may allow
the Doudna-Charpentier team to petition the
US Patent and Trademark Office (USPTO) to
challenge Zhang’s initial patent through an
“interference proceeding” if their application
is ultimately rejected6. The stakes for an interference proceeding would be high: if Doudna
and Charpentier were to win, Zhang’s earliest

patent would be invalidated, although there
would be no guarantee that the DoudnaCharpentier patent application would be
granted. If Zhang were to win, he would keep
his initial patent, and Doudna and Charpentier
would likely walk away empty handed.
The second challenge concerns the patents’
scope. All of the CRISPR patent applications
filed thus far are drafted quite broadly. As a
consequence, if the USPTO allows these patent applications to move forward—and if the
patents are ultimately enforced—the patents
are likely to prevent even the most basic use
of the CRISPR-Cas9 system without a license.
General academic research would almost certainly be liable for patent infringement7. At
the same time, the patent statute immunizes
research performed in connection with submitting new drug or biologic information to
the US Food and Drug Administration8. Thus,
depending on the enforcement scheme and the
technology’s development, academic research
may be subject to claims of patent infringement
while some commercial development may proceed unchecked.
Last, the patents themselves pose several questions concerning their validity.
Specifically, patent claims that are “obvious”
may be declared “invalid” and may be freely
used by others9. In the biotechnology context,
there has been a long-running and unresolved
issue about whether certain applications of a
technology are obvious once the fundamentals
of a technology (such as PCR) are known. Now
that the mechanics of CRISPR-Cas9 are known,
have genome-editing applications become
obvious? Answering that question in legal
terms is immensely difficult, but the answer is
likely to control the future of all CRISPR-Cas9
patent disputes.
Historical precedents
Whether and how these difficulties are
resolved will be largely up to the assignees of
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the dueling patent applications: UC Berkeley,
the University of Vienna, the Massachusetts
Institute of Technology (MIT) and the Broad
Institute. The history of licensing patents
on earlier foundational technologies—
recombinant DNA, small interfering RNA
(siRNA) and PCR—provide several avenues
for deploying CRISPR-Cas9 without lengthy
patent fights. Stanford University’s management of the Cohen-Boyer patents on recombinant DNA, for example, has become the gold
standard for university technology licensing10. First, the patents’ assignee, Stanford,
licensed the technology nonexclusively and
allowed nonprofit research institutions to
use the technology without a license. Second,
the university developed a graduated royalty
system to ensure that smaller companies were
not disadvantaged. And finally, Stanford preemptively consulted a wide variety of stakeholders and experimented with different
licensing agreements, to much community
fanfare.
Another helpful example to consider is
MIT’s ‘Tuschl patents’ on siRNA technology. As with CRISPR-Cas9, overly restrictive licensing could have significantly slowed
scientific progress. MIT, however, was able to
avert this problem through licensing. The uni-

versity currently allows academic scientists
with laboratory-made versions of the molecular components to use the technology for free
and grants companies selling these molecular components nonexclusive licenses11. The
startup Alnylam, however, has received an
exclusive license to the technology for therapeutic applications.
The PCR patents provide another option
for licensing and deployment. Because the
technology was discovered in the context of
industry, strong enforcement of PCR patents
could have significantly hindered scientific
progress. This problem was largely mitigated, however, through the twin policies of
‘rational forbearance’ from suing researchers for patent infringement and the adoption
of widespread corporate licensing, business
partnerships and adaptive licensing strategies12. In this way, PCR was widely—and
quickly—disseminated.
Although these examples are quite different
from one another, in all cases, the assignees
chose an appropriate and user-specific combination of enforcement and licensing. Choosing
the right strategy or strategies may help the
CRISPR-Cas9 patent assignees to avert legal
challenges, realize significant revenue streams
and promote scientific progress simultaneously.

Conclusion
CRISPR-Cas9 is a very promising tool in the
quest for genome editing. Whether the technology is allowed to develop with patent protection will be up to law and history, rather
than science.
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